Concentrations of Th17 and Proinflammatory Cytokines in Culture Supernatant in Children Before and After Vaccination With WRSS1
| . | . | Concentration, pg/mL . | |||
|---|---|---|---|---|---|
| Cytokine . | Dose Group . | Baseline . | Day 7 . | Day 35 . | Day 63 . |
| IL-17 | Placebo (n = 12) | 108.3 (98.1–129.6) | 133.7 (83.3–147.5) | 118.8 (86.1–144.8) | 132.9 (93.6–209.4) |
| 4-log (n = 8) | 109.4 (79.2–156.2) | 117.2 (84.8–154.1) | 129.1 (116.4–153.2) | 166.1 (157.9–186.3) | |
| 5-log (n = 11) | 72.9 (34.5–143.5) | 99.5 (68.7–147.3) | 159.5 (125.4–207.4)*§ | 107.9 (54.7–127.5) | |
| 6-log (n = 10) | 115.5 (100.9–146.5) | 97.3 (86.0–118.8) | 87.9 (70.4–118.8) | 221.1 (141.7–285.7)* | |
| TNF-α | Placebo (n = 12) | 211.3 (190.9–276.3) | 223.5 (153.1–303.4) | 200.0 (162.6–306.8) | 235.9 (190.4–406.6) |
| 4-log (n = 8) | 218.2 (166.7–358.0) | 254.1 (189.1–378.1) | 256.9 (237.8–287.4) | 373.8 (304.2–472.3) | |
| 5-log (n = 11) | 139.0 (57.7–296.0) | 173.3 (84.7–252.7)* | 335.8 (288.9–372.0)*§ | 214.6 (121.4–288.1) | |
| 6-log (n = 10) | 226.2 (169.3–265.4) | 175.9 (150.2–211.8) | 158.7 (117.7–238.4) | 325.5 (216.8–805.8)* | |
| MIP-1β | Placebo (n = 12) | 84.3 (50.4–228.1) | 69.3 (55.7–228.6) | 158.6 (65.8–294.0) | 207.4 (26.7–613.8) |
| 4-log (n = 8) | 45.7 (27.2–57.4) | 161.1 (24.6–328.7) | 112.9 (68.1–122.8) | 219.9 (63.7–460.0)* | |
| 5-log (n = 11) | 25.3 (17.3–63.8)§ | 72.6 (55.7–401.6)* | 162.4 (24.9–208.9)* | 31.5 (9.2–179.5) | |
| 6-log (n = 10) | 159.8 (94.3–261.0) | 227.4 (154.9–307.5)*§ | 234.3 (142.2–268.2) | 490.8 (201.8–662.1)* | |
| G-CSF | Placebo (n = 12) | 775 (416–2227) | 675 (385–2218) | 595 (316–2375) | 1319 (642–3542) |
| 4-log (n = 8) | 1830 (1208–3106) | 1998 (983–2747)§ | 2171 (1785–2866) | 4853 (2757–7276)*§§§ | |
| 5-log (n = 11) | 561 (98–1978) | 1070 (172–1740) | 2190 (1503–3294)* | 824 (308–2066) | |
| 6-log (n = 10) | 484 (377–596) | 471 (338–579) | 324 (141–535) | 1060 (330–1499)* | |
| . | . | Concentration, pg/mL . | |||
|---|---|---|---|---|---|
| Cytokine . | Dose Group . | Baseline . | Day 7 . | Day 35 . | Day 63 . |
| IL-17 | Placebo (n = 12) | 108.3 (98.1–129.6) | 133.7 (83.3–147.5) | 118.8 (86.1–144.8) | 132.9 (93.6–209.4) |
| 4-log (n = 8) | 109.4 (79.2–156.2) | 117.2 (84.8–154.1) | 129.1 (116.4–153.2) | 166.1 (157.9–186.3) | |
| 5-log (n = 11) | 72.9 (34.5–143.5) | 99.5 (68.7–147.3) | 159.5 (125.4–207.4)*§ | 107.9 (54.7–127.5) | |
| 6-log (n = 10) | 115.5 (100.9–146.5) | 97.3 (86.0–118.8) | 87.9 (70.4–118.8) | 221.1 (141.7–285.7)* | |
| TNF-α | Placebo (n = 12) | 211.3 (190.9–276.3) | 223.5 (153.1–303.4) | 200.0 (162.6–306.8) | 235.9 (190.4–406.6) |
| 4-log (n = 8) | 218.2 (166.7–358.0) | 254.1 (189.1–378.1) | 256.9 (237.8–287.4) | 373.8 (304.2–472.3) | |
| 5-log (n = 11) | 139.0 (57.7–296.0) | 173.3 (84.7–252.7)* | 335.8 (288.9–372.0)*§ | 214.6 (121.4–288.1) | |
| 6-log (n = 10) | 226.2 (169.3–265.4) | 175.9 (150.2–211.8) | 158.7 (117.7–238.4) | 325.5 (216.8–805.8)* | |
| MIP-1β | Placebo (n = 12) | 84.3 (50.4–228.1) | 69.3 (55.7–228.6) | 158.6 (65.8–294.0) | 207.4 (26.7–613.8) |
| 4-log (n = 8) | 45.7 (27.2–57.4) | 161.1 (24.6–328.7) | 112.9 (68.1–122.8) | 219.9 (63.7–460.0)* | |
| 5-log (n = 11) | 25.3 (17.3–63.8)§ | 72.6 (55.7–401.6)* | 162.4 (24.9–208.9)* | 31.5 (9.2–179.5) | |
| 6-log (n = 10) | 159.8 (94.3–261.0) | 227.4 (154.9–307.5)*§ | 234.3 (142.2–268.2) | 490.8 (201.8–662.1)* | |
| G-CSF | Placebo (n = 12) | 775 (416–2227) | 675 (385–2218) | 595 (316–2375) | 1319 (642–3542) |
| 4-log (n = 8) | 1830 (1208–3106) | 1998 (983–2747)§ | 2171 (1785–2866) | 4853 (2757–7276)*§§§ | |
| 5-log (n = 11) | 561 (98–1978) | 1070 (172–1740) | 2190 (1503–3294)* | 824 (308–2066) | |
| 6-log (n = 10) | 484 (377–596) | 471 (338–579) | 324 (141–535) | 1060 (330–1499)* | |
Data are median (interquartile range). Statistical significance between pre- and postvaccination days within group was determined using Wilcoxon Signed rank test. Kruskal-Wallis test was applied to compare vaccine groups with placebo at each time point. *P ≤ .05 when comparison was made between pre- and postvaccination days. §P ≤ .05; §§§P ≤ .005 when vaccine groups were compared with placebo.
Abbreviations: G-CSF, granulocyte colony-stimulating factor; IL-17, interleukin 17; MIP-1β, macrophage inflammatory protein-1β; TNF-α, tumor necrosis factor-α.
Concentrations of Th17 and Proinflammatory Cytokines in Culture Supernatant in Children Before and After Vaccination With WRSS1
| . | . | Concentration, pg/mL . | |||
|---|---|---|---|---|---|
| Cytokine . | Dose Group . | Baseline . | Day 7 . | Day 35 . | Day 63 . |
| IL-17 | Placebo (n = 12) | 108.3 (98.1–129.6) | 133.7 (83.3–147.5) | 118.8 (86.1–144.8) | 132.9 (93.6–209.4) |
| 4-log (n = 8) | 109.4 (79.2–156.2) | 117.2 (84.8–154.1) | 129.1 (116.4–153.2) | 166.1 (157.9–186.3) | |
| 5-log (n = 11) | 72.9 (34.5–143.5) | 99.5 (68.7–147.3) | 159.5 (125.4–207.4)*§ | 107.9 (54.7–127.5) | |
| 6-log (n = 10) | 115.5 (100.9–146.5) | 97.3 (86.0–118.8) | 87.9 (70.4–118.8) | 221.1 (141.7–285.7)* | |
| TNF-α | Placebo (n = 12) | 211.3 (190.9–276.3) | 223.5 (153.1–303.4) | 200.0 (162.6–306.8) | 235.9 (190.4–406.6) |
| 4-log (n = 8) | 218.2 (166.7–358.0) | 254.1 (189.1–378.1) | 256.9 (237.8–287.4) | 373.8 (304.2–472.3) | |
| 5-log (n = 11) | 139.0 (57.7–296.0) | 173.3 (84.7–252.7)* | 335.8 (288.9–372.0)*§ | 214.6 (121.4–288.1) | |
| 6-log (n = 10) | 226.2 (169.3–265.4) | 175.9 (150.2–211.8) | 158.7 (117.7–238.4) | 325.5 (216.8–805.8)* | |
| MIP-1β | Placebo (n = 12) | 84.3 (50.4–228.1) | 69.3 (55.7–228.6) | 158.6 (65.8–294.0) | 207.4 (26.7–613.8) |
| 4-log (n = 8) | 45.7 (27.2–57.4) | 161.1 (24.6–328.7) | 112.9 (68.1–122.8) | 219.9 (63.7–460.0)* | |
| 5-log (n = 11) | 25.3 (17.3–63.8)§ | 72.6 (55.7–401.6)* | 162.4 (24.9–208.9)* | 31.5 (9.2–179.5) | |
| 6-log (n = 10) | 159.8 (94.3–261.0) | 227.4 (154.9–307.5)*§ | 234.3 (142.2–268.2) | 490.8 (201.8–662.1)* | |
| G-CSF | Placebo (n = 12) | 775 (416–2227) | 675 (385–2218) | 595 (316–2375) | 1319 (642–3542) |
| 4-log (n = 8) | 1830 (1208–3106) | 1998 (983–2747)§ | 2171 (1785–2866) | 4853 (2757–7276)*§§§ | |
| 5-log (n = 11) | 561 (98–1978) | 1070 (172–1740) | 2190 (1503–3294)* | 824 (308–2066) | |
| 6-log (n = 10) | 484 (377–596) | 471 (338–579) | 324 (141–535) | 1060 (330–1499)* | |
| . | . | Concentration, pg/mL . | |||
|---|---|---|---|---|---|
| Cytokine . | Dose Group . | Baseline . | Day 7 . | Day 35 . | Day 63 . |
| IL-17 | Placebo (n = 12) | 108.3 (98.1–129.6) | 133.7 (83.3–147.5) | 118.8 (86.1–144.8) | 132.9 (93.6–209.4) |
| 4-log (n = 8) | 109.4 (79.2–156.2) | 117.2 (84.8–154.1) | 129.1 (116.4–153.2) | 166.1 (157.9–186.3) | |
| 5-log (n = 11) | 72.9 (34.5–143.5) | 99.5 (68.7–147.3) | 159.5 (125.4–207.4)*§ | 107.9 (54.7–127.5) | |
| 6-log (n = 10) | 115.5 (100.9–146.5) | 97.3 (86.0–118.8) | 87.9 (70.4–118.8) | 221.1 (141.7–285.7)* | |
| TNF-α | Placebo (n = 12) | 211.3 (190.9–276.3) | 223.5 (153.1–303.4) | 200.0 (162.6–306.8) | 235.9 (190.4–406.6) |
| 4-log (n = 8) | 218.2 (166.7–358.0) | 254.1 (189.1–378.1) | 256.9 (237.8–287.4) | 373.8 (304.2–472.3) | |
| 5-log (n = 11) | 139.0 (57.7–296.0) | 173.3 (84.7–252.7)* | 335.8 (288.9–372.0)*§ | 214.6 (121.4–288.1) | |
| 6-log (n = 10) | 226.2 (169.3–265.4) | 175.9 (150.2–211.8) | 158.7 (117.7–238.4) | 325.5 (216.8–805.8)* | |
| MIP-1β | Placebo (n = 12) | 84.3 (50.4–228.1) | 69.3 (55.7–228.6) | 158.6 (65.8–294.0) | 207.4 (26.7–613.8) |
| 4-log (n = 8) | 45.7 (27.2–57.4) | 161.1 (24.6–328.7) | 112.9 (68.1–122.8) | 219.9 (63.7–460.0)* | |
| 5-log (n = 11) | 25.3 (17.3–63.8)§ | 72.6 (55.7–401.6)* | 162.4 (24.9–208.9)* | 31.5 (9.2–179.5) | |
| 6-log (n = 10) | 159.8 (94.3–261.0) | 227.4 (154.9–307.5)*§ | 234.3 (142.2–268.2) | 490.8 (201.8–662.1)* | |
| G-CSF | Placebo (n = 12) | 775 (416–2227) | 675 (385–2218) | 595 (316–2375) | 1319 (642–3542) |
| 4-log (n = 8) | 1830 (1208–3106) | 1998 (983–2747)§ | 2171 (1785–2866) | 4853 (2757–7276)*§§§ | |
| 5-log (n = 11) | 561 (98–1978) | 1070 (172–1740) | 2190 (1503–3294)* | 824 (308–2066) | |
| 6-log (n = 10) | 484 (377–596) | 471 (338–579) | 324 (141–535) | 1060 (330–1499)* | |
Data are median (interquartile range). Statistical significance between pre- and postvaccination days within group was determined using Wilcoxon Signed rank test. Kruskal-Wallis test was applied to compare vaccine groups with placebo at each time point. *P ≤ .05 when comparison was made between pre- and postvaccination days. §P ≤ .05; §§§P ≤ .005 when vaccine groups were compared with placebo.
Abbreviations: G-CSF, granulocyte colony-stimulating factor; IL-17, interleukin 17; MIP-1β, macrophage inflammatory protein-1β; TNF-α, tumor necrosis factor-α.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
